Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
Open Access
Abstract
Objectives This study assessed the psychometric properties of the fatigue numeric rating scale (NRS) and sought to establish values for clinically meaningful change (responder definition). Methods Using disease-specific clinician-reported and patient-reported data from two randomised clinical trials of patients with psoriatic arthritis (PsA), the fatigue NRS was evaluated for test–retest reliability, construct validity and responsiveness. A responder definition was also explored using anchor-based and distribution-based methods. Results Test–retest reliability analyses supported the reproducibility of the fatigue NRS in patients with PsA (intraclass correlation coefficient=0.829). Mean (SD) values at baseline and week 2 were 5.7 (2.2) and 5.7 (2.4), respectively. Supporting construct validity of the fatigue NRS, moderate-to-large correlations with other assessments measuring similar concepts as measured by Sackett’s conventions were demonstrated. Fatigue severity was reduced when the underlying disease activity was improved and reductions remained consistent at week 12 and 24. A 3-point improvement was identified as being optimal for demonstrating a level of clinically meaningful improvement in fatigue NRS after 12–24 weeks of treatment. Conclusions Fatigue NRS is a valid and responsive patient-reported outcome instrument for use in patients with PsA. The established psychometric properties from this study support the use of fatigue NRS in clinical trials and in routine clinical practice. Robust validation of reliability for use in routine clinical practice in treating patients with active PsA in less active disease states and other more diverse ethnic groups is needed.Keywords
Funding Information
- Eli Lilly and Company
This publication has 45 references indexed in Scilit:
- Measuring Disease Activity in Psoriatic ArthritisInternational Journal of Rheumatology, 2012
- Interpreting patient-reported outcome results: US FDA guidance and emerging methodsExpert Review of Pharmacoeconomics & Outcomes Research, 2011
- Longitudinal Analysis of Fatigue in Psoriatic ArthritisThe Journal of Rheumatology, 2010
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 2010
- Occurrence and correlates of fatigue in psoriatic arthritisAnnals of the Rheumatic Diseases, 2009
- Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritisRheumatology, 2009
- On Association Coefficients for 2×2 Tables and Properties That Do Not Depend on the Marginal DistributionsPsychometrika, 2008
- Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritisAnnals of the Rheumatic Diseases, 2007
- Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis TrialAnnals of the Rheumatic Diseases, 2007
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995